ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ

ᱣᱤᱠᱤᱯᱤᱰᱤᱭᱟ ᱠᱷᱚᱱ
Jump to navigation Jump to search
ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ
Mirabegron.svg
Clinical data
Trade names Myrbetriq, Betanis, Betmiga, others
Synonyms YM-178
AHFS/Drugs.com Monograph
data
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration
By mouth (tablets)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 29–35%[᱑]
Protein binding 71%[᱑]
Metabolism Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase[᱑]
Elimination half-life 50 hours[᱑]
Excretion Urine (55%), faeces (34%)[᱑]
Identifiers
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard 100.226.392
Chemical and physical data
Formula C21H24N4O2S
Molar mass 396.506 g/mol g·mol−1
3D model (JSmol)

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ(ᱤᱸᱞᱤᱥ ᱯᱟᱹᱨᱥᱤᱛᱮ Mirabegron, ᱢᱤᱫ ᱟᱹᱠᱷᱨᱤᱧ ᱧᱩᱛᱢ ᱢᱤᱨᱵᱮᱴᱨᱤᱠ/ Myrbetriq) ,ᱱᱚᱣᱟ ᱢᱤᱫ ᱨᱟᱱ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ ᱛᱤᱠᱪᱷᱟᱹᱨᱮ(overactive bladder) ᱵᱮᱵᱷᱟᱨᱚᱜᱼᱟ।[᱒] ᱚᱠᱥᱤᱵᱭᱩᱴᱤᱱ (oxybutynin) ᱞᱮᱠᱟ ᱟᱱᱴᱤᱢᱚᱥᱠᱟᱨᱤᱱ ᱨᱟᱱ(antimuscarinic medication) ᱠᱷᱚᱱ ᱠᱚᱢᱜᱮᱠᱚ ᱯᱚᱥᱚᱸᱫᱼᱟ। [᱓] ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱚᱪᱟ ᱨᱮᱠᱚ ᱮᱢᱚᱜᱼᱟ ।[᱒]

ᱢᱤᱨᱟᱵᱮᱜᱨᱚᱱ ᱨᱮᱱᱟᱜ ᱚᱨᱥᱚᱝ ᱛᱮ ᱥᱚᱠᱛᱚ ᱢᱟᱭᱟᱢ ᱪᱟᱯ , ᱵᱚᱦᱚᱜ ᱦᱟᱹᱥᱩ, ᱪᱩᱰᱩ ᱱᱟᱞᱟ ᱜᱷᱟᱣ ᱠᱚ ᱦᱩᱭ ᱫᱟᱲᱟ ᱦᱟᱜᱼᱟ ।[᱒] ᱱᱚᱣᱟ ᱵᱟᱫ ᱠᱟᱛᱮ ᱟᱧᱤᱭᱳᱭᱤᱰᱤᱢᱟ, ᱚᱦᱤᱥᱟᱹᱵ ᱡᱤᱣᱤᱪᱟᱹᱞᱩ irregular heart rate ᱟᱨ ᱭᱩᱨᱤᱱᱟᱨᱤ ᱨᱤᱴᱮᱱᱥᱚᱱ ᱦᱩᱭᱫᱟᱲᱮ ᱦᱟᱜᱼᱟ ।[᱒][᱓] ᱱᱚᱣᱟ ᱵᱤᱴᱟᱼ᱓ ᱟᱰᱨᱮᱱᱡᱤᱠ ᱨᱤᱥᱮᱯᱴᱚᱨᱼᱮ (β3 adrenergic receptor) ᱪᱮᱸᱜᱷᱟ ᱦᱚᱪᱚ ᱠᱷᱟᱹᱛᱤᱨ ᱪᱩᱰᱩᱛᱷᱩᱞᱤ (bladder) ᱚᱪᱚᱲᱚᱜᱼᱟ । [᱓][᱒]

ᱰᱟᱠᱛᱚᱨᱤ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱫ ᱒᱐᱑᱒ ᱥᱟᱞ ᱨᱮ ᱭᱩ ᱮᱥ ᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱢᱟᱱᱚᱛ ᱮ ᱮᱢ ᱞᱮᱫ ᱛᱟᱦᱮᱸᱫ ।[᱔][᱒] ᱒᱐᱑᱙ ᱥᱟᱞ ᱨᱮ ᱭᱩᱱᱟᱭᱴᱮᱰ ᱠᱤᱝᱰᱚᱢᱨᱮ (United Kingdom) ᱮᱱᱮᱪᱮᱥ (NHS) ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮᱱᱟᱜ ᱰᱳᱡ ᱯᱤᱪᱷᱟᱹ ᱒᱙ ᱯᱟᱶᱰ ᱞᱮᱠᱟ ᱠᱷᱚᱨᱚᱪ ᱦᱩᱭ ᱟᱭ ᱠᱟᱱ ᱛᱟᱦᱮᱸᱫ ।[᱓] ᱭᱩ ᱮᱥ ᱮ ᱨᱮ ᱢᱤᱫ ᱪᱟᱸᱫᱚ ᱨᱮ ᱱᱚᱣᱟ ᱨᱮᱱᱟᱜ ᱦᱳᱞᱥᱮᱞ ᱫᱟᱢ ᱓᱖᱙ ᱟᱢᱮᱨᱤᱠᱟ ᱰᱚᱞᱟᱨ ᱠᱟᱱᱟ ।[᱕] ᱒᱐᱑᱖ ᱥᱟᱞ ᱨᱮ ᱱᱚᱣᱟ ᱨᱟᱱ ᱑ᱱᱤᱭᱩᱛ ᱠᱷᱚᱱ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱞᱮᱱ ᱠᱷᱟᱹᱛᱤᱨ ᱡᱟᱹᱥᱛᱤ ᱯᱨᱮᱥᱠᱨᱤᱯᱥᱚᱱ ᱦᱟᱠᱟᱱ ᱨᱟᱱ ᱨᱮᱱᱟᱜ ᱛᱟᱹᱞᱠᱟᱹᱨᱮ ᱒᱖᱓ ᱟᱱᱟᱜ ᱴᱷᱟᱶ ᱮ ᱟᱢᱮᱴ ᱞᱮᱫᱼᱟ ।[᱖]

ᱥᱟᱹᱠᱷᱭᱟᱹᱛ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

  1. ᱑.᱐ ᱑.᱑ ᱑.᱒ ᱑.᱓ ᱑.᱔ "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 ᱱᱚᱵᱷᱮᱢᱵᱚᱨ 2013. 
  2. ᱒.᱐ ᱒.᱑ ᱒.᱒ ᱒.᱓ ᱒.᱔ ᱒.᱕ "Mirabegron Monograph for Professionals". Drugs.com (in English). American Society of Health-System Pharmacists. Retrieved 18 ᱢᱟᱨᱪ 2019. 
  3. ᱓.᱐ ᱓.᱑ ᱓.᱒ ᱓.᱓ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 763. ISBN 9780857113382. 
  4. Sacco, E; Bientinesi, R; et al. (ᱮᱯᱨᱤᱞ 2014). "Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence". Expert Opin Drug Discov. 9 (4): 433–48. doi:10.1517/17460441.2014.892923. PMID 24559030. 
  5. "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in English). Retrieved 3 ᱢᱟᱨᱪ 2019. 
  6. "The Top 300 of 2019". clincalc.com. Retrieved 22 ᱰᱤᱥᱮᱢᱵᱚᱨ 2018. 

ᱵᱟᱦᱨᱮ ᱡᱚᱱᱚᱲ[ᱥᱟᱯᱲᱟᱣ | ᱯᱷᱮᱰᱟᱛ ᱥᱟᱯᱲᱟᱣ]

  • Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology. 4 (6): 315–24. doi:10.1177/1756287212457114. PMC 3491758. PMID 23205058.